NASDAQ:TNDM - Tandem Diabetes Care Stock Price, Forecast & News

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Tandem Diabetes Care's stock reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

Tandem Diabetes Care Inc (NASDAQ:TNDM) issued its earnings results on Tuesday, April, 30th. The medical device company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.10. The medical device company had revenue of $66 million for the quarter, compared to the consensus estimate of $47.55 million. The business's revenue for the quarter was up 141.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.82) EPS. View Tandem Diabetes Care's Earnings History.

Tandem Diabetes Care is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Tandem Diabetes Care.

Tandem Diabetes Care will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

14 analysts have issued 12-month target prices for Tandem Diabetes Care's shares. Their forecasts range from $65.00 to $100.00. On average, they anticipate Tandem Diabetes Care's stock price to reach $79.79 in the next year. This suggests that the stock has a possible downside of 7.3%. View Analyst Price Targets for Tandem Diabetes Care.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tandem Diabetes Care.

News headlines about TNDM stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Tandem Diabetes Care earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned headlines about the medical device company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Tandem Diabetes Care.

Tandem Diabetes Care saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 6,970,000 shares, an increase of 17.7% from the December 31st total of 5,920,000 shares. Based on an average trading volume of 1,460,000 shares, the days-to-cover ratio is presently 4.8 days. Currently, 12.5% of the shares of the stock are sold short. View Tandem Diabetes Care's Current Options Chain.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Ryder System (R), Pandora Media (P), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Tesla (TSLA) and Paypal (PYPL).

Tandem Diabetes Care's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (3.97%), Fred Alger Management LLC (2.43%), State Street Corp (2.26%), Delphi Management Partners VIII L.L.C. (1.69%), Eagle Asset Management Inc. (1.67%) and Goldman Sachs Group Inc. (1.27%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Richard P Valencia and Susan Morrison. View Institutional Ownership Trends for Tandem Diabetes Care.

TNDM stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Lord Abbett & CO. LLC, Fred Alger Management LLC, Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Marshall Wace North America L.P., Driehaus Capital Management LLC and Columbus Circle Investors. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller and Susan Morrison. View Insider Buying and Selling for Tandem Diabetes Care.

TNDM stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Delphi Management Partners VIII L.L.C., Jennison Associates LLC, Perceptive Advisors LLC, UBS Asset Management Americas Inc., J. Goldman & Co LP, Parkman Healthcare Partners LLC and Goldman Sachs Group Inc.. Company insiders that have bought Tandem Diabetes Care stock in the last two years include Dick Allen and Richard P Valencia. View Insider Buying and Selling for Tandem Diabetes Care.

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TNDM stock can currently be purchased for approximately $86.03.